COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa (ADD201)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00983814
Recruitment Status : Completed
First Posted : September 24, 2009
Last Update Posted : April 4, 2013
Information provided by (Responsible Party):
Chelsea Therapeutics

Brief Summary:

Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty waiting and interrupting others. ADHD is the second most common neuropsychiatric disorder affecting 4.4% of the US adult population, or between 8-9 million individuals (Kessler et al., 2006).

Droxidopa (L-dihydroxyphenylserine (L-DOPS)) is a synthetic catecholamine which is converted to norepinephrine (NE) via decarboxylation, resulting in increased levels of NE centrally in the CNS and peripherally. Co-treatment with carboxylase inhibitors, such as carbidopa, given with droxidopa, can increase the CNS levels of NE with greater crossing of the blood-brain barrier. Droxidopa has received orphan drug approval by the FDA for the treatment of symptomatic neurogenic orthostatic hypotension in individuals with primary autonomic failure. The half-life of droxidopa is approximately 2-3 hours, resulting in administration thee times daily.

As adult ADHD is characterized as a disorder of decreased NE activity in the pre-frontal cortex, it is hypothesized that treating patients with droxidopa (in co-administration of carbidopa) will have a positive effect on adult ADHD.

Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Drug: Droxidopa+Carbidopa Drug: Placebo Phase 2

Detailed Description:
This will be a 12-week study of twenty enrolled subjects with DSM IV adult ADHD (age 18-55), with a goal of completing twenty subjects in the trial. The primary objective of this study is to determine the effect of droxidopa therapy on adult ADHD symptoms over the course of a six-week open-label titration period followed by a two-week double-blind, placebo-controlled period. The primary outcome measure will be changes from baseline in total score on the Adult ADHD Investigator Symptom Rating Scale (AISRS). Secondary measures will be changes in self-report ADHD symptoms on the ASRS v1.1 Symptom Checklist, global impairment on the Clinician Global Impression Scale (CGI).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Two-Period Trial (Open-Label and Randomized Placebo-Controlled Substitution) of Droxidopa Treatment in Adults With ADHD With Co-administration of Carbidopa
Study Start Date : October 2009
Actual Primary Completion Date : May 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Droxidopa+Carbidopa
Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID)
Drug: Droxidopa+Carbidopa
Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID, provided as oral capsules taken TID from Baseline to end of Week 8
Other Names:
  • Droxidopa
  • L-threo-dihydroxyphenylserine
  • L-DOPS

Placebo Comparator: Placebo
Drug: Placebo
Placebo matched oral capsules taken TID from Baseline to end of Week 8

Primary Outcome Measures :
  1. The primary outcome measure will be changes from baseline in total score on the Adult ADHD Investigator Symptom Rating Scale (AISRS). [ Time Frame: Baseline to end of week 8 treatment ]

Secondary Outcome Measures :
  1. Changes in self-report ADHD symptoms on the ASRS v1.1 Symptom Checklist [ Time Frame: baseline to end of 8 Week treatment period ]
  2. Changes in global impairment on the Clinician Global Impression Scale (CGI). [ Time Frame: baseline to end of week 8 treatment period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. At the time of consent, are between the ages of 18-55, inclusive.
  2. Meet DSM-IV criteria for ADHD as assessed by the Adult ADHD Clinician Diagnostic Scale (ACDS) v1.2.
  3. Concomitant Axis I diagnoses that are allowed include social anxiety disorder or dysthymia which does not require treatment. Psychiatric co-morbidities will be diagnosed with the SCID.
  4. Must have a satisfactory medical assessment with no clinically significant abnormalities as determined by medical history, physical exam, ECG, and clinical laboratory testing.
  5. Must be able to swallow capsules.
  6. In the opinion of the investigator, the subject must understand and be able, willing and likely to fully comply with the study procedures and restrictions.
  7. Must have given signed and dated informed consent in accordance with Good Clinical Practice (GCP) Guidelines.

Exclusion Criteria:

  1. Lifetime or present history of bipolar or psychotic disorders, that in the investigator's opinion, interfere with the diagnosis and/or with the conduct of the study.
  2. Uncontrolled comorbid major depressive disorder, anxiety disorder or dysthymia.
  3. Women of childbearing potential who are not using a medically accepted contraception.
  4. Sexually active males whose partner is a WOCP must agree to use condoms for the duration of the study and for 4 weeks after the last dose.
  5. Women who are pregnant, breast feeding, or plan to become pregnant during the course of this study.
  6. Clinically significant electrocardiogram or laboratory abnormalities at screening that are deemed exclusionary in the opinion of the Principal Investigator.
  7. Subjects taking any psychotropic medication on a regular basis. Subjects will need to be free of all psychotropic medications (one week for psychostimulants, four weeks for all other medications), except for PRN benzodiazepines or hypnotics. Allowed psychiatric co-morbidities include social anxiety disorder or dysthymia which does not require treatment.
  8. Subjects with any concurrent chronic or acute illness or unstable medical condition that could, in the opinion of the study physician, confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol. Subjects who have a history of mental retardation or severe learning disability will be excluded.
  9. Subjects who in the investigator's opinion meet any of the exclusionary criteria specified on the FDA label of either Droxidopa or carbidopa.
  10. Have uncontrolled hypertension, defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >110 mmHg or use of ≥2 antihypertensive medications.
  11. Known or suspected hypersensitivity to the study medication or any of its ingredients.
  12. Have in the investigator's opinion any significant cardiac arrhythmia.
  13. Any significant systemic, hepatic, cardiac or renal illness.
  14. Diabetes mellitus or insipidus.
  15. Have a history of closed angle glaucoma.
  16. Have a known or suspected current malignancy. Patients with a history of cancer must be symptom- and treatment-free for at least 5 years prior to randomization, with the exception of patients with non-melanoma, non-invasive skin cancers (such as basal cell carcinoma), who should not have had an intervention or recurrence within one year of starting the study.
  17. Subjects with known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug.
  18. In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing.
  19. In the investigator's opinion, are unable to adequately co-operate because of individual or family situation.
  20. Are not able or willing to comply with the study requirements for the duration of the study.
  21. Have participated in another clinical trial with an investigational agent (including named patient or compassionate use protocol) within 1 month before the start of the study.
  22. Previous enrollment in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00983814

Layout table for location information
United States, New York
VA New York Harbor Healthcare System/New York University Langone Medical Center
New York, New York, United States, 10010
Sponsors and Collaborators
Chelsea Therapeutics
Layout table for investigator information
Principal Investigator: Lenard A Adler, M.D. VA New York Harbor Healthcare System/New York University Langone Medical Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Chelsea Therapeutics Identifier: NCT00983814    
Other Study ID Numbers: Droxidopa ADD201
First Posted: September 24, 2009    Key Record Dates
Last Update Posted: April 4, 2013
Last Verified: March 2013
Keywords provided by Chelsea Therapeutics:
Attention Deficit Hyperactivity Disorder
Adult ADHD
Adult Attention Deficit Hyperactivity Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Attention Deficit Disorder with Hyperactivity
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors